Expert Review of Neurotherapeutics最新文献_第4页

Advances in the medical treatment and diagnosis of intracranial hemorrhage associated with oral anticoagulation. 与口服抗凝药有关的颅内出血的医疗和诊断进展。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-09-01 Epub Date: 2024-07-22 DOI: 10.1080/14737175.2024.2379413

Claudio Piqueras-Sanchez, María Asunción Esteve-Pastor, Jorge Moreno-Fernandez, Eva Soler-Espejo, José Miguel Rivera-Caravaca, Vanessa Roldán, Francisco Marín

{"title":"Advances in the medical treatment and diagnosis of intracranial hemorrhage associated with oral anticoagulation.","authors":"Claudio Piqueras-Sanchez, María Asunción Esteve-Pastor, Jorge Moreno-Fernandez, Eva Soler-Espejo, José Miguel Rivera-Caravaca, Vanessa Roldán, Francisco Marín","doi":"10.1080/14737175.2024.2379413","DOIUrl":"10.1080/14737175.2024.2379413","url":null,"abstract":"Introduction: With the increasing prevalence of atrial fibrillation (AF), it entails expanding oral anticoagulants (OACs) use, carrying a higher risk of associated hemorrhagic events, including intracranial hemorrhage (ICH). Despite advances in OACs development with a better safety profile and reversal agent for these anticoagulants, there is still no consensus on the optimal management of patients with OACs-associated ICH.Areas covered: In this review, the authors have carried out an exhaustive search on the advances in recent years. The authors provide an update on the management of ICH in anticoagulated patients, as well as an update on the latest evidence on anticoagulation resumption, recent therapeutic strategies, and investigational drugs that could play a role in the future.Expert opinion: Following an ICH event in an anticoagulated patient, a comprehensive clinical evaluation is imperative. Anticoagulation should be promptly withdrawn and reversed. Once the patient is stabilized, a reintroduction of anticoagulation should be considered, typically within a timeframe of 4-8 weeks, if feasible. If re-anticoagulation is not possible, alternative options such as Left Atrial Appendage Occlusion are available.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"913-928"},"PeriodicalIF":3.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141747846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gantenerumab for early Alzheimer's disease: a systematic review and meta-analysis. 甘特宁单抗治疗早期阿尔茨海默病：系统综述和荟萃分析。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-09-01 Epub Date: 2024-06-16 DOI: 10.1080/14737175.2024.2367016

Artur Menegaz de Almeida, Marianna Leite, Lucca Moreira Lopes, Pedro Gomes Lima, Maria Luísa Siegloch Barros, Samuel Rocha Pinheiro, Ítalo Andrade, Patrícia Viana, Victória Morbach, Gabriel Marinheiro, Ricardo de Oliveira, Agostinho C Pinheiro

{"title":"Gantenerumab for early Alzheimer's disease: a systematic review and meta-analysis.","authors":"Artur Menegaz de Almeida, Marianna Leite, Lucca Moreira Lopes, Pedro Gomes Lima, Maria Luísa Siegloch Barros, Samuel Rocha Pinheiro, Ítalo Andrade, Patrícia Viana, Victória Morbach, Gabriel Marinheiro, Ricardo de Oliveira, Agostinho C Pinheiro","doi":"10.1080/14737175.2024.2367016","DOIUrl":"10.1080/14737175.2024.2367016","url":null,"abstract":"Introduction: Gantenerumab is a monoclonal antibody targeting amyloid β protein (Aβ) in early Alzheimer's disease (AD). The authors sought to evaluate gantenerumab safety and efficacy in early AD patients.Methods: MEDLINE, Embase, and Cochrane databases were systematically searched until 2 December 2023. Data were examined using the Mantel-Haenszel method and 95% confidence intervals (CIs). Meta-regression analysis was conducted to evaluate a possible link between baseline Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) and amyloid-related imaging abnormalities (ARIA) at follow-up. R, version 4.2.3, was used for statistical analysis.Results: A total of 4 RCTs and 2848 patients were included, of whom 1580 (55%) received subcutaneous gantenerumab. Concerning clinical scores, the placebo group achieved better rates of change in the Disease Assessment Scale (ADAS-Cog13) (SMD -0.11; 95% CI -0.19- -0.03; p = 0.008569; I2 = 0%). Gantenerumab was strongly associated with the occurrence of ARIA-E and ARIA-H: (19.67% vs. 2.31%; RR 9.46; 95% CI 5.55-16.11; p = <0.000001; I2 = 10%) and (21.95% vs. 12.38%; RR 1.79; 95% CI 1.50-2.13; p = <0.000001; I2 = 0%), respectively.Discussion: In this meta-analysis, consistent results suggest that gantenerumab is not safe and efficient for early AD, showing no improvement in clinical scores for AD and being associated with the occurrence of ARIA-E and ARIA-H.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"929-936"},"PeriodicalIF":3.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141327373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Profiling the combination of bupropion and dextromethorphan as a treatment option for major depressive disorder. 分析安非他酮和右美沙芬的组合作为治疗重度抑郁障碍的一种选择。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-09-01 Epub Date: 2024-07-22 DOI: 10.1080/14737175.2024.2374024

Joseph Blanco, Pamela Quimbaya, Manuel Mena, Seetal Dodd, Rosa-Helena Bustos

{"title":"Profiling the combination of bupropion and dextromethorphan as a treatment option for major depressive disorder.","authors":"Joseph Blanco, Pamela Quimbaya, Manuel Mena, Seetal Dodd, Rosa-Helena Bustos","doi":"10.1080/14737175.2024.2374024","DOIUrl":"10.1080/14737175.2024.2374024","url":null,"abstract":"Introduction: Major Depressive Disorder (MDD) is a common mental health disorder marked by sadness, hopelessness, and anhedonia. Various therapies exist, but their effectiveness is limited. Dextromethorphan hydrobromide combined with bupropion hydrochloride (Auvelity®) is a recently approved alternative for treating this condition in adults.Areas covered: This review summarizes the neurobiology of major depression and delves into the pharmacology, efficacy, safety, and tolerability of dextromethorphan plus bupropion in adult patients. It is based on observational studies, clinical trials, and other secondary studies obtained through systematic literature searches.Expert opinion: The combination of bupropion and dextromethorphan as a new pharmacotherapy for mental health is an interesting addition to the treatment options that can be used for MDD. The combination can be used in a range of scenarios, including as a first line therapy, as a second option when a patient has failed to achieve remission with a serotonin targeting agent, and for treatment resistant depression. Further research for other indications, including addiction disorders, may provide exciting results. Although a new combination, clinicians will be very familiar with both agents, increasing their acceptability. This pharmacotherapy also may bring increased impetus for discovering other combinations that may have beneficial synergistic effects.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"837-848"},"PeriodicalIF":3.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141747847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Re-evaluating the prognosis of schizophrenia: tackling the issue of inadequate treatment. 重新评估精神分裂症的预后：解决治疗不当的问题。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-09-01 Epub Date: 2024-06-16 DOI: 10.1080/14737175.2024.2365943

Ofer Agid

引用次数: 0

Risk of suicide and suicide-related events in subjects treated with antiseizure medications. 接受抗癫痫药物治疗的受试者自杀和自杀相关事件的风险。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-09-01 Epub Date: 2024-07-08 DOI: 10.1080/14737175.2024.2376110

Boulenouar Mesraoua, Francesco Brigo, Bassel Abou-Khalil, Musab Ali, Simona Lattanzi

{"title":"Risk of suicide and suicide-related events in subjects treated with antiseizure medications.","authors":"Boulenouar Mesraoua, Francesco Brigo, Bassel Abou-Khalil, Musab Ali, Simona Lattanzi","doi":"10.1080/14737175.2024.2376110","DOIUrl":"10.1080/14737175.2024.2376110","url":null,"abstract":"Introduction: In the United States, it is reported that 1.4% of the general population commits suicide. It has been postulated that antiseizure medications (ASMs) can lead to the development of suicidal ideation and suicidal behavior; however, this risk is still very low and has yet to be precisely established.Areas covered: This narrative review evaluates the risk of suicide-related events (SREs) in subjects taking ASMs for various neurological disorders. Screening tools for suicidal ideation and suicidal behavior are also discussed. References for this article were found using PubMed/MEDLINE.Expert opinion: Although some ASMs can be associated with SREs, this is not yet clearly established. The mechanisms involved in suicide risk in subjects taking ASMs are multifactorial. The bidirectional relationship between depression and epilepsy, as well as other associations, should be kept in mind when interpreting any impact of ASMs in PWE. Screening for SREs, close monitoring of subjects taking ASMs are the most appropriate strategies to minimize suicide risk. More efforts should be made to achieve accurate risk stratification through prognostic models that could be applied to subjects taking ASMs. Studies exploring the association between ASMs and suicide should consider ASMs individually and control for prior SREs.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"865-878"},"PeriodicalIF":3.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141558438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Are ketamine and its enantiomers the answer to treatment-refractory depression? 氯胺酮及其对映体是治疗难治性抑郁症的答案吗？

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-09-01 Epub Date: 2024-06-27 DOI: 10.1080/14737175.2024.2373302

Jean-Baptiste Belge, Gabrielle Scantamburlo, Eric Constant

引用次数: 0

Profiling deutetrabenazine extended-release tablets for tardive dyskinesia and chorea associated with Huntington's disease. 对治疗与亨廷顿氏病有关的迟发性运动障碍和舞蹈症的丁乙拉拉嗪缓释片进行分析。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-09-01 Epub Date: 2024-07-09 DOI: 10.1080/14737175.2024.2376107

P Moondra, J Jimenez-Shahed

{"title":"Profiling deutetrabenazine extended-release tablets for tardive dyskinesia and chorea associated with Huntington's disease.","authors":"P Moondra, J Jimenez-Shahed","doi":"10.1080/14737175.2024.2376107","DOIUrl":"10.1080/14737175.2024.2376107","url":null,"abstract":"Introduction: Tardive dyskinesia (TD) and Huntington's disease (HD)-associated chorea are persistent and disabling hyperkinetic disorders that can be treated with vesicular monoamine transporter type 2 (VMAT2) inhibitors, including the recently approved once-daily (QD) formulation of deutetrabenazine (DTBZ ER). While its efficacy and safety profile have not been directly investigated, currently available data confirms bioequivalence and similar bioavailability to the twice-daily formulation (DTBZ BID).Areas covered: The authors briefly review the pivotal trials establishing efficacy of DTBZ for TD and HD-associated chorea, the pharmacokinetic data for bioequivalence between QD and BID dosing of DTBZ, as well as dose proportionality evidence, titration recommendations, and safety profile for DTBZ ER.Expert opinion: Long-term data show that DTBZ is efficacious and well tolerated for the treatment of TD and HD-associated chorea. DTBZ ER likely demonstrates therapeutic equivalence with no new safety signals. Due to the lack of comparative clinical trial data, no evidence-based recommendation about choice of VMAT2 inhibitor or switching between VMAT2 inhibitors can be made about best practice. Ultimately, QD dosing may offer the chance of improved medication adherence, an important consideration in patients with complex treatment regimens and/or patients with cognitive decline.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"849-863"},"PeriodicalIF":3.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141563082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in gene therapy for high-grade glioma: a review of the clinical evidence. 高级别胶质瘤基因治疗的进展：临床证据综述。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-09-01 Epub Date: 2024-08-01 DOI: 10.1080/14737175.2024.2376847

Matthew J Goldman, Alexandra M Baskin, Martyn A Sharpe, David S Baskin

{"title":"Advances in gene therapy for high-grade glioma: a review of the clinical evidence.","authors":"Matthew J Goldman, Alexandra M Baskin, Martyn A Sharpe, David S Baskin","doi":"10.1080/14737175.2024.2376847","DOIUrl":"10.1080/14737175.2024.2376847","url":null,"abstract":"Introduction: High-grade glioma (HGG) is one of the most deadly and difficult cancers to treat. Despite intense research efforts, there has not been a significant breakthrough in treatment outcomes since the early 2000's. Anti-glioma gene therapy has demonstrated promise in preclinical studies and is under investigation in numerous clinical trials.Areas covered: This manuscript reviews the current landscape of clinical trials exploring gene therapy treatment of HGG. Using information from clinicaltrials.gov, all trials initiated within the past 5 years (2018-2023) as well as other important trials were cataloged and reviewed. This review discusses trial details, innovative methodologies, and concurrent pharmacological interventions. The review also delves into the subtypes of gene therapy used, trends over time, and future directions.Expert opinion: Trials are in the early stages (phase I or II), and there are reports of clinical efficacy in published results. Synergistic effects utilizing immunotherapy within or alongside gene therapy are emerging as a promising avenue for future breakthroughs. Considerable heterogeneity exists across trials concerning administration route, vector selection, drug combinations, and intervention timing. Earlier intervention in newly diagnosed HGG and avoidance of corticosteroids may improve efficacy in future trials. The results from ongoing trials demonstrate promising potential for molding the future landscape of HGG care.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"879-895"},"PeriodicalIF":3.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141874557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The importance of synthetic pharmacotherapy for recessive cerebellar ataxias. 合成药物疗法对隐性小脑性共济失调的重要性。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-09-01 Epub Date: 2024-07-09 DOI: 10.1080/14737175.2024.2376840

Marie Beaudin, Nicolas Dupre, Mario Manto

{"title":"The importance of synthetic pharmacotherapy for recessive cerebellar ataxias.","authors":"Marie Beaudin, Nicolas Dupre, Mario Manto","doi":"10.1080/14737175.2024.2376840","DOIUrl":"10.1080/14737175.2024.2376840","url":null,"abstract":"Introduction: The last decade has witnessed major breakthroughs in identifying novel genetic causes of hereditary ataxias, deepening our understanding of disease mechanisms, and developing therapies for these debilitating disorders.Areas covered: This article reviews the currently approved and most promising candidate pharmacotherapies in relation to the known disease mechanisms of the most prevalent autosomal recessive ataxias. Omaveloxolone is an Nrf2 activator that increases antioxidant defense and was recently approved for treatment of Friedreich ataxia. Its therapeutic effect is modest, and further research is needed to find synergistic treatments that would halt or reverse disease progression. Promising approaches include upregulation of frataxin expression by epigenetic mechanisms, direct protein replacement, and gene replacement therapy. For ataxia-telangiectasia, promising approaches include splice-switching antisense oligonucleotides and small molecules targeting oxidative stress, inflammation, and mitochondrial function. Rare recessive ataxias for which disease-modifying therapies exist are also reviewed, emphasizing recently approved therapies. Evidence supporting the use of riluzole and acetyl-leucine in recessive ataxias is discussed.Expert opinion: Advances in genetic therapies for other neurogenetic conditions have paved the way to implement feasible approaches with potential dramatic benefits. Particularly, as we develop effective treatments for these conditions, we may need to combine therapies, consider newborn testing for pre-symptomatic treatment, and optimize non-pharmacological approaches.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"897-912"},"PeriodicalIF":3.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141558439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Why does exposure-based therapy fail in some individuals with obsessive-compulsive disorder? 为什么暴露疗法在某些强迫症患者身上会失败？

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-08-01 Epub Date: 2024-06-14 DOI: 10.1080/14737175.2024.2365949

Benedikt Reuter, Annemarie Miano, Josepha Wassermann, Björn Elsner

引用次数: 0